💨 Abstract

Sangamo Therapeutics Inc. (SGMO) reported a second-quarter loss of $20 million, or 8 cents per share, missing Wall Street's forecast of a 7 cents per share loss. The company's revenue was $18.3 million. The biotech firm's results fell short of analyst expectations.

Courtesy: WTOP Staff